Toledo Data Fail To Give Galapagos A Lift

Underwhelming Results For Lead SIK Inhibitor

15 Jul 2021

Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.

Iguana — Galapagos pipeline stuck again • Source: Shutterstock

Initial data from Galapagos NV's closely watched Toledo program, seen as key to the future hopes for the embattled Belgian biotech, have failed to impress analysts or investors, with the stock heading south again.

Galapagos's pipeline has been a cause of concern since October 2020 when the osteoarthritis drug GLPG1972, an ADAMTS-5 inhibitor partnered with Servier, failed to significantly reduce cartilage loss in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

26 May 2025

• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.